Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Bristol Shores Up Cancer, NASH Pipelines With International Deals

Executive Summary

Partnership with France’s Enterome will add a microbiome aspect to Bristol’s immuno-oncology efforts, while its license of Japanese firm Nitto Denko’s siRNA technology could bolster NASH combo therapy development. Meanwhile, Eagle moves into biosimilars with the purchase of Arsia for up to $78m.

Advertisement

Related Content

Finance Watch: J&J Notes JLabs Incubators' Success Stories To Date
Enterome Building A Microbiome R&D Presence Via Pharma Deals
Novartis Buys Selexys As Competitors Stumble In Sickle Cell
Combination Strategies A Common Thread In NASH R&D
Chiesi Takes Aim At Next-Generation Eosinophilic Asthma Therapy
Bayer, Evotec Alliances Create 'Virtual' Specialized Businesses With Finite Goals
Merck KGAA Invests €260m In Production Value Chain in China
Teva Hits Pause On Business Development, Even As Some Deals Stumble
Seventure Partners Fund Focuses On Microbiome Revolution
Enterome Extends Its Microbiome Platform

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097716

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel